A formulation for use as a therapeutic product, wherein the formulation comprises: (a) a mixture of at least one phosphate derivative of a monoelectronic transfer agent and at least one phosphate derivative of a dielectronic transfer agent； where the electronic transfer agent is selected from the group consisting of hydroxychromans, stumps and tocotrienols in enantiomeric and racemic forms； quinoles which are the reduced forms of vitamin K1 and ubiquinone； and hydroxycarotenoids； and where the molar ratio between the phosphate derivative of the monoelectronic transfer agent and the phosphate derivative of the dielectronic transfer agent is in the range of 85:15 to 65:35； and (b) a suitable carrier. wherein an emulsion type composition is excluded for therapeutic administration comprising: a) at least one phosphate derivative of a monoelectronic transfer agent； b) at least one phosphate derivative of a dielectronic transfer agent； where the electronic transfer agent is selected from the group consisting of hydroxychromans, stumps and tocotrienols in enantiomeric and racemic forms； quinoles which are the reduced forms of vitamin K1 and ubiquinone； and hydroxycarotenoids； and where the molar ratio between the phosphate derivative of the monoelectronic transfer agent and the phosphate derivative of the dielectronic transfer agent is in the range of 85:15 to 65:35； and c) a suitable carrier.Una formulación para su uso como producto terapéutico, donde la formulación comprende: (a) una mezcla de al menos un derivado de tipo fosfato de un agente de transferencia monoelectrónica y al menos un derivado de tipo fosfato de un agente de transferencia dielectrónica； donde el agente de transferencia electrónica se selecciona entre el grupo formado por hidroxicromanos, tocoles y tocotrienoles en formas enantioméricas y racémicas； quinoles que son las formas reducidas de la vitamina K1 y la ubiquinona； e hidroxicarotenoides； y donde la relación molar entre el derivado de tipo fosfat
